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Abstract
We present an unusual case of a young woman with rare bilateral, very
aggressive ovarian granulosa cell tumour (GCT), comprised of granulosa,
sarcomatoid and fibrothecomatous fields with significantly different
immunostaining of primary and metastatic tumours showing stronger WT1, Bcl2,
fascin and EGFR expression in metastases. Despite radical surgery and
chemotherapy the tumour recurred rapidly and the patient died 16 months later.
Such results clearly demonstrate the usefulness of immunostaining for the above
markers as prognostic/predictive factors and the need for careful assessment
of the immunoprofile of both primary and metastatic tumours, which can be
useful for therapy and follow-up planning in GCT cases.
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Introduction
Granulosa cell tumours (GCTs) are rare tumours, accounting for 2-5%
of primary ovarian tumours, that develop unilaterally (> 95% of cases) in
peri- and postmenopausal women. The tumour behaviour is difficult to
predict. Little information about definitive prognostic markers, except for
the stage, has been reported [1]. These tumours have malignant potential,
although metastasis or recurrence usually occurs late, as much as 20-30
years following the primary diagnosis [2].
Here we report an unusual case of a young woman who developed
bilateral ovarian GCTs with a very aggressive course, rapid recurrence, and
a short time of survival. We examined the immunostaining pattern of
a broad range of markers, trying to identify indicators of this phenotype
of GCT.
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Case report
A 35-year-old nulliparous woman was admitted
to the Department of Gynaecological Oncology,
Oncology Centre, Bydgoszcz, Poland, for a re-
laparotomy. Three months earlier, she underwent
a laparotomy. During the surgical procedure, an
encapsulated tumour 30 cm in diameter, filling the
small pelvis, in adhesion with the sigmoid colon and
lesser omentum, was found. The tumour was
enucleated. The intraoperative pathological exami  -
nation results were ambiguous and revealed only
the presence of atypical cells. Due to young age,
nulliparous status and imprecise histopatho  logical
diagnosis, the decision concerning possible radical
surgery was postponed until an unequivocal
diagnosis could be obtained. The postoperative
material was consulted at the Maria Skłodowska-
Curie Memorial Cancer Centre and Institute of
Oncology, Warsaw, Poland and the malignant lesion
was diagnosed. Before the second laparotomy,
ultrasonography revealed only a solid cystic mass
in the left ovary. Tumour markers were normal (AFP
3.11 IU/ml, CA-125 19.51 U/ml and CEA 0.4 U/ml).
At the re-laparotomy, a left ovarian tumour 7 cm in
diameter and an 8 cm tumour of the small intestine
adherent to the sigmoid and left appendages were
discovered. The patient underwent a radical
hysterectomy, and tumour masses in the mesentery
of the small intestine and in the colon were
removed with clear margins. The tumour comprised
mainly atypical fibrothecomatous and sarcomatoid
patterns, with a trace of granulosa cell diffe  -
rentiation surrounded by spindle-shaped stromal
cells. The mesenteric and colonic tumours
comprised sarcomatoid and sarcomatoid/fibro  -
thecomatous components, respectively. Histoche  -
mistry and immunocytochemistry indicated GCT
(Figure 1). The tumours comprised more than 60%
Ki67-positive cells and numerous cells with bizarre
nuclei. The immunophenotypes of the ovarian,
mesenteric, and colonic tumours differed (Table I,
Figure 2). Immunostaining for CD56, CD99, and
calretinin was negative in the sarcomatoid areas,
and their expression levels were lower in fields with
mixed fibrothecomatous and sarcomatoid diffe  -
rentiations than in fibrothecomatous regions of the
tumour. Moreover, the metastatic cells showed
stronger and more extensive staining for CD117 and
CK AE1/3 (both components), and weaker or no
staining for calretinin and CK MNF116. Both the
ovarian and metastatic tumours were negative for
Figure 1. Histopathological and immunohistochemical features of malignant granulosa cell tumour. The tumour was
composed predominantly of sarcomatoid (A) and thecomatous (B-D) cells with vacuolated cytoplasm. A trace of
Call-Exner bodies differentiation type was also seen (E). Tumour cells stained positively for calretinin (F), CD56 (G),
CD99 (H), and vimentin (I). Immunoreactivity was visualized with DAB, and the sections were counterstained with
haematoxylin. Scale bars = 50 μm
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p73, p63, p53, CA125, desmin, CD34, E-cadherin,
CK5/6, CK20, and CK HMW. Although HER2
immunostaining was negative, chromogenic in situ
hybridization revealed an increased number of HER2
gene copies assessed according to a breast cancer
evaluation protocol (Zymed Inc.,) up to 4.4 and 2.1
copies per bizarre and non-bizarre nuclei,
respectively.
Ten days after surgery, positron emission
tomography-computed tomography revealed no
abnormal fluorodeoxyglucose uptake. The patient
received bleomycin, etoposide, and cisplatin
combination chemotherapy (3 courses, total dose
of bleomycin was 1800 mg (9 administrations),
etoposide – 210 mg (7 administrations) and cisplatin
– 495 mg (9 administrations)). Systematic follow-up
examination was performed every 2 months. Lung
X-ray and NMR (nuclear magnetic resonance)
imaging at 6 months and abdominal cavity
ultrasound examinations 6 and 8 months after the
re-laparotomy revealed no atypical findings. 
The serum levels of tumour markers after the 
re-laparotomy (examined 6 times) were normal 
(CA-125 from 12.74 U/ml to 15.72 U/ml; LDH from
221 U/l to 395 U/l, AFP from 3.92 ng/ml to 
7.01 ng/ml, HCG from 0 mIU/ml to 0.73 mIU/ml, CEA
from 0.8 ng/ml to 1.1 ng/ml and Ca 15-3 from 
11.9 U/ml to 13.3U/ml). Tumour recurrence ensued
after a 14-month asymptomatic course, and a lesion
measuring 6 cm × 5.3 cm × 12.0 cm infiltrating the
bladder wall was diagnosed with NMR imaging. The
patient received palliative radiotherapy (20 Gy in five
fractions of 400 cGy; Co-60 radiation/6 MV/15 MV).
The patient died 16 months after the re-laparotomy.
Discussion
The dynamics of the carcinogenesis process,
which affect the biological malignancy of the
tumour, are regulated by various genetic and
epigenetic factors, including microenvironment and
status and condition of the immune system [2, 3].
Tissue changes during the menstrual cycle or
pregnancy can reflect epigenetic and micro-
environmental hormonal regulation, which can also
affect the development and progression of the
tumour [2-4]. Epithelial cancers, arising in women
mostly within organs related to reproduction (ovary,
breast, cervix), seem to be highly sensitive to
hormonal changes, particularly in younger patients. 
The GCTs metastasize and recur only in 20% of
patients 10 years after the original diagnosis.
However, in our patient the tumour recurred very
rapidly, despite radical surgery and chemotherapy.
The stage at the time of diagnosis is the most
important prognostic factor of GCTs. It is very
important to identify new markers that could help
to predict aggressive course, rapid recurrence or
chemotherapy response. There are only a few
immunohistochemical prognostic markers in GCTs
[1, 5]. One of our purposes was to determine the
immunostaining profile of an ovarian metastatic
GCT and indicate potential prognostic markers.
The tumour of our patient showed the
expression of sex cord-stromal marker (calretinin)
and a very high mitotic index (28/10 HPF) compared
with most patients with a GCT (< 5/10 HPF) [2, 5].
Unlike McCluggage et al. [6], who reported on
a malignant fibrothecomatous tumour belonging
to the same group of sex cord-stromal tumours as
GCTs, we observed different immunophenotypes in
the primary and metastatic neoplasms. We found
very clear expression of WT1, in contrast to Cathro
and Stoler [7], who found weak or variable WT1
expression. High expression of WT1 can be related
to an unfavourable prognosis in tumour patients
[8]. In vitro studies show that cell lines expressing
WT1 and Bcl2 are resistant to chemotherapeutic
agents [9]. In our patient, WT1-induced upregulation
of antiapoptotic Bcl2 protein might have caused
chemoresistance of the metastatic sarcomatoid
Marker Tumour Immunostaining 
(intensity/% 
of area; 
localization)
EGFR Primary –
Mesenteric –
Colonic: sarcomatoid field –
Colonic: thecomatous field +/75; C
WT1 Primary +/10; C
Mesentery +/5; C
Colonic: sarcomatoid field ++/30; +++/20; C
Colonic: thecomatous field –
Bcl2 Primary +/1; C
Mesentery –
Colonic: sarcomatoid field ++/20; C
Colonic: thecomatous field –
ERβ Primary +/70; C, N
Mesentery +/35; ++/50; C, N
Colonic: sarcomatoid field ++/70; C, N
Colonic: thecomatous field ++/100; C, N
Fascin Primary +++/90; C
Mesentery ++/45; +++/40; C
Colonic: sarcomatoid field +/10; ++/50; 
+++/30; C
Colonic: thecomatous field +/50; C
Table I. Expression of selected markers of the primary
and metastatic (mesenteric and colonic) tumours
C – cytoplasmic staining, N – nuclear staining. Staining intensity was
scored as follows: negative –, weak +, moderate ++, and strong +++
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cells. Similarly, chemoresistance of fibrotheco  -
matous cells and more aggressive course might
have resulted from overexpression of EGFR [10, 11].
Weaker and less abundant expression of fascin
within the metastatic tumours might indicate
a more favourable prognosis [12], although in our
patient, its expression was as strong within the
sarcomatoid component as in the primary tumour.
In our patient, the greater expression of EGFR, 
Bcl-2, and WT1 in the metastatic lesions and fascin
in the primary tumour seemed to be a predictor of
the poor course of GCT and to reflect a more
aggressive phenotype, which might indicate early
recurrence.
In conclusion, our findings indicate the possible
existence of a fundamental difference between
Figure 2. Malignant granulosa cell tumour showing different immunophenotype of the primary and metastatic lesions.
Immunoreactivity was visualized with DAB, and the sections were counterstained with haematoxylin. Scale bars 
= 100 μm
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primary and metastatic cells. These results also
indicate the need for more aggressive therapy of
GCTs with stronger WT1, Bcl2, fascin, and EGFR
expression in the metastases. Immunostaining for
the above markers may provide potential predictors
of GCT malignancy. We cannot exclude the
possibility that metastatic expression of ERβ and
EGFR might suggest the usefulness of hormone and
anti-EGFR therapy, respectively.
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